ClinicalTrials.gov
public full text
Public Domain
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study. The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the best standard of care.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Argatroban Stroke Treatment - A Pilot Safety Study#829745
- Imatinib in Acute Ischaemic Stroke#1259823
- Senicapoc and Perampanel for Newly Diagnosed Glioblastoma#891053
- Comparative effectiveness of Tenecteplase and Alteplase for ischemic stroke : real-world data from a stroke center#1390957
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours#874742
Record · ID 1381904
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive